Donepezil SR 23 mg Tablets BE study [Study Per­for­mance]

posted by madhavaraob – 2010-07-07 09:27 (5423 d 17:24 ago) – Posting: # 5597
Views: 12,877

Dear all,

We are planning to conduct a bioequivalence study on Donepezil SR 23 mg tablets in comparision with 10 mg IR tablets for US regulatory. We would like to know whether this study is feasible to be conducted in healthy population or in patients?
If the study need to be conducted in patients, what is the severity of the diseased condition (mild/moderate/severe) to be selected?

With Regards,

Madhav

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
66 visitors (0 registered, 66 guests [including 41 identified bots]).
Forum time: 02:51 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5